Sign in
Active, not recruitingPhase 1

A Study to Evaluate the Safety, Tolerability, PK and PD of Intracerebroventricular GC1123 in Patients with MPS Ⅱ

Key facts

Who runs it
GC Biopharma Corp
Where
South Korea3 sites in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
Phase
Phase 1
People taking part
12 people, planned
Started
20 Sept 2022
Expected to end
Jun 2027
Type of study
Interventional
Treatments tested
  • GC1123
Record updated
15 October 2024

Who can take part

Age
18 months to 18 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Patient who has been diagnosed with severe MPS Ⅱ (Hunter syndrome)
  • Patient, aged 1.5 years (18 months) to 18 years at the time of the screening
  • Patient who has received and tolerated a minimum of 12 weeks of treatment with weekly intravenous treatment, and who has received 80% of the total planned infusions within that time frame
  • Patient who is capable of undergoing neurosurgery, which has been confirmed by neurosurgeons and anesthesiologist
  • Patient eligible to execute patient evaluation activities during the clinical trial period, as assessed by the investigator
  • Patient whose parents or legal representative are willing to participate in this clinical trial and provide written informed consent form

Who cannot take part

  • Patient who has received treatment with any investigational drug or device within 30 days prior to study entry
  • Patient who have experience of hypersensitivity or anaphylaxis to ingredients of the investigational product at the time of screening
  • Patient with a history of bone marrow transplantation or cord blood transplant
  • Patient with a history of ventriculoperitoneal shunt or other intracranial surgeries
  • Patient with end-stage multiple organ dysfunction syndrome or other severe diseases
  • Patient who is exposed to malignant neoplasm
  • Patient with a history of bronchotomy/tracheostomy, or patient with acute respiratory disease at the time of screening
  • Patient who is ineligible to participate in the clinical trial due to laboratory test results or other reasons, as determined by the investigator
  • Patient who has been administered with intrathecal Idursulfase in the past

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of intracerebroventricular GC1123 in patients with MPS Ⅱ who have central nervous system involvement and are receiving treatment with intravenous drug

The group in the trial

  • GC1123 30mgTreatment being tested

    30 mg of IP will be administered every 28 days for all enrolled patients

    Treatment: GC1123

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Open-Label, Phase 1 and Extension Study to Evaluate the Safety, Tolerability, PK and PD of Intracerebroventricular GC1123 in Patients with MPS Ⅱ Who Have Central Nervous System Involvement and Are Receiving Treatment with Intravenous Drug
Record updated
15 October 2024